Skip to main content
 
 
 
 
InstantAtlas Server Logo
InstantAtlas™ Server 6
 
 
 
 
  Log In

Metadata: Indicator Instance

18-64 yrs at increased risk, white only, non-Hispanic | Local Area | 2015

Name Value Link
breaks 0, 100  
maxChartValue 100  
metatext

Data Notes:

• Coverage estimates are for adults ≥18 years who completed a BRFSS interview during 2008-2018.

• Estimates for the United States and HHS Regions exclude U.S. territories.

• Pneumococcal vaccination was determined by asking respondents if they had ever received a pneumonia shot. Vaccination with pneumococcal polysaccharide vaccine is recommended for adults 18-64 years at increased risk for pneumococcal disease and all adults ≥65 years. In 2008-2010, adults were considered at increased risk if they self-reported one or more of the following: 1) current asthma; 2) ever having diabetes, myocardial infarction, angina or coronary heart disease; or 3) being a current smoker. In 2011-2018, adults were considered at increased risk if they self-reported any of the previous conditions, or ever having chronic obstructive pulmonary disease, emphysema or chronic bronchitis, or cancer (excluding skin cancer). Vaccination with 13-valent pneumococcal conjugate vaccine in series with pneumococcal polysaccharide vaccine is recommended for adults ≥19 years with an immunocompromising condition, CSF leak, or cochlear implant. There are no questions in the BRFSS to ascertain type of pneumococcal vaccine received.

• Tetanus vaccination is determined by asking respondents if they have received a tetanus shot in the past 10 years. Vaccinated respondents included adults who received tetanus diphtheria toxoid vaccine (Td) or tetanus, diphtheria, and acellular pertussis vaccine (Tdap). During 2013-2017, respondents were asked if they had received a tetanus shot since 2005. At least one Tdap vaccination is recommended: every 10 years for adults ≥18 years; during every pregnancy, ideally in the third trimester; and, for health care personnel (HCP). Starting in January 2020, either Td or Tdap can be used for the 10-year booster.

• Herpes zoster vaccination was determined by asking respondents ≥50 years if they had ever received a shingles or zoster vaccine. Prior to 2017, herpes zoster vaccination was recommended for all adults ≥60 years. In October 2017, the recommendation was updated to include all adults ≥50 years and vaccination with recombinant zoster vaccine is preferred over zoster vaccine live. There are no questions in the BRFSS to ascertain type of herpes zoster vaccine received (recombinant or live).

• Questions regarding receipt of tetanus and herpes zoster vaccination are included on the BRFSS questionnaire for all states every three years on a rotating basis. Some states include these questions in intervening years.

• Race/ethnicity is based on self-report. Persons categorized as white, black, or other or multiple race identified as non-Hispanic. Persons identifying as Hispanic might be of any race. The other or multiple race category included persons identifying as Asian, American Indian and Alaska Native, Native Hawaiian or other Pacific Islander, other races, or multiple races. Persons identifying as multiple race selected more than one race category.

Abbreviations:

• CI = 95% confidence interval half-width.

• % = weighted percentage of population vaccinated. Percentages are weighted to the non-institutionalized, U.S. population.

• NR = Not reported.

• HP 2020 target = Healthy People 2020 coverage levels established to reduce the burden of vaccine preventable diseases.

• NaN = Not applicable.

Footnotes:

* Data not collected.

 
minChartValue 0  

* Indicator instance level metadata

 

InstantAtlas™ Server (IAS) v6.6.0